Illumina Launches New Genomic AI Model for Rare Disease Research
MT Newswires Live
Oct 08
Illumina (ILMN) said Thursday it launched new genomic AI model SpliceAI2 to support rare disease research projects.
The new model allows researchers to identify disease-relevant splice variants, the company said.
When applied to a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared with other splicing models, Illumina said.
SpliceAI2 may be accessed through the BioInsight applications, the company said.
Illumina shares were down 3.9% in Thursday trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.